InvestorsHub Logo
Followers 43
Posts 2387
Boards Moderated 0
Alias Born 08/09/2016

Re: AVII77 post# 192451

Saturday, 10/06/2018 11:10:44 AM

Saturday, October 06, 2018 11:10:44 AM

Post# of 730105
AVI - Thanks. Key differences between this study and the DCVAX study are that this Phase II trial only followed patients for a maximum of 5 years, and there was no crossover. This seems to limit their ability to capture "long tail" survivors, who would make the OS number better. I fully expect DCVAX to fail on PFS. I think the long delay in unblinding the DCVAX trial is because of exactly these issues - extending OS to the max is their one chance at success.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News